Gastroparesis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

The prevalence of cases of Gastroparesis in the USA is 268 to 339 cases per 100,000 population in the USA was more than twice as common in females than in male individuals, highest in patients aged 58 to 64 years, and lowest in patients aged 18 to 27 years. The prevalence of diabetic gastroparesis ranges between 101 to 105 cases, per 100,000 persons, whereas the prevalence of diabetic gastroparesis among patients with type 1 and type 2 diabetes was 10.4 and 91.0.

Read more:- Gastroparesis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Gastroparesis-forecast

Comprehensive insight on patient segmentation based on age, sex, by etiology (T1DM, T2DM, Postsurgical, Drug-induced, Idiopathic, and Other types; Scleroderma, Lupus, Hypothyroidism, Parkinson disease, Cerebral palsy, Multiple sclerosis) and others undefined, severity (Mild, Moderate, and severe), Settings; Refractory cases, Signs & Symptoms, Clinical Manifestations, and has been provided into the epidemiology section of the Gastroparesis and its treatment in the 8 MM countries, covering the United States, EU5 (Germany, Spain, France, Italy, UK), Japan, and China

CI IMAGE

In terms of pharmacologic therapies, there are few drug candidates/biologicals are in different Phase (Phase I, II & III) stages of development. Key companies are Theravance Biopharma, PTC Therapeutics, CinDome Pharma, Inc., Vanda Pharmaceuticals, GlaxoSmithKline, Bird Rock Bio, Inc., Evoke Pharma, Neurogastrx, Inc., Ironwood Pharmaceuticals, Inc., Takeda, Millennium Phar-maceuticals, Inc., Forest Laboratories, Motus Therapeutics, Inc., and few others. Gastroparesis (GP) has long been in dire need of novel therapies, given the aggressive nature and poor prognosis in the refractory setting. One of the major limitations to drug development is that clinical trials tend to enroll a large number of Gastroparesis severity.

 

About Thelansis:

Thelansis is specialized in pharmaceutical market research and market Insight Report Company, published reports across the therapeutic area which includes both rare / ultra-rare and mainstream indication. Over the period of time, we have built a strong repository of 6,000+ Bio-pharma reports which essentially covers Epidemiology study and Market forecasting based on the KOL opinions. Competitive intelligence and track of trial results throughout the phases of development executed by a team of a mix of Scientific and Business backgrounds. As an organization, the major focus is to provide real-world data evidence and market insight to pharmaceutical companies for their decision-making.

 

Other Reports:-
GM2 Gangliosidosis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Lyme Disease – Market Outlook, Epidemiology, Competitive Landscape and Market Forecast Report – 2020 To 2030

Subarachnoid hemorrhage (SAH) – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

ANCA-Associated Vasculitis – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

Factor VII Deficiency – Market outlook, Epidemiology, Market Forecast and Competitive Landscape Report – 2020 To 2030

 

Contact details:-

Gurugram- Onework Gold Souk mall, Phase I, Sector 43, Haryana-122002, India

Contact no.: +91(124) 404-1731

Sales office

183-Asylum Street Hartford, CT-06103, USA

USA +1 (267) 244-6955,

Email

clientsupport@thelansis.com

m.berg@thelansis.com

Tags: Gastroparesis, Gastroparesis market outlook report, Gastroparesis competitive landscape, Gastroparesis market forecast